Hepion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to advancing the treatment of chronic liver disease through the development of innovative, pleiotropic drug therapies. Chronic liver disease is a complex and growing global health issue that affects millions of people worldwide, and Hepion Pharmaceuticals is committed to addressing this unmet medical need through the advancement of their drug development programs.
The company's research and development efforts are focused on the discovery and development of novel drug candidates that target multiple pathways of liver disease, with the ultimate goal of providing safe and effective therapies that improve patient outcomes. Hepion Pharmaceuticals is a leader in the field of liver disease research and is poised to make a significant impact on the lives of patients suffering from this debilitating condition.
Novel Mechanism of Action That Targets Multiple Pathways
One of Hepion's lead drug candidates is CRV431, a cyclophilin inhibitor with a novel mechanism of action that targets multiple pathways involved in the progression of chronic liver disease. CRV431 has demonstrated antifibrotic, anti-inflammatory, and antiviral activity in preclinical studies, and is currently being evaluated in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
Hepion is also developing additional drug candidates, including ARO-APOC3 for the treatment of hypertriglyceridemia and ARO-HSD for the treatment of nonalcoholic fatty liver disease (NAFLD). These drug candidates are based on Hepion's proprietary AI-POWR™ (Artificial Intelligence – Precision Medicine; Omics-based World Recognition) platform, which utilizes advanced computational tools to identify novel drug targets and optimize drug development.
Leading Clinical Development of the Lead Drug Candidate
Todd M. Hobbs is the Chief Medical Officer (CMO) of Hepion Pharmaceuticals. As CMO, Dr. Hobbs is responsible for overseeing the company's clinical development programs and guiding the development of Hepion's drug candidates from preclinical testing to regulatory approval and commercialization. Dr. Hobbs brings over 20 years of experience in clinical practice, academic medicine, and industry to his role at Hepion Pharmaceuticals.
Innovative Approach to Liver Disease Treatment
Hepion's approach to treating chronic liver disease is based on the understanding that liver disease is a complex, multifactorial condition that requires a comprehensive therapeutic approach. The company's drug candidates are designed to target multiple pathways involved in liver disease progression, including inflammation, fibrosis, and metabolic dysfunction.
Future Outlook and Growth Strategy
Looking ahead, Hepion is well-positioned to advance its pipeline of investigational therapies and continue its mission of developing breakthrough treatments for chronic liver diseases. The company's strong scientific foundation, experienced leadership team, and commitment to innovation position it for continued growth and success in the competitive biopharmaceutical landscape.